Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Next steps in understanding the genetics behind MS severity

Genome-wide analysis of multiple sclerosis (MS) severity in over 22,000 cases has identified a novel locus associated with long-term MS outcomes. Adil Harroud, MD, McGill University, Montreal, Canada, shares some of the implications of this study and the next steps for continuing this line of research. Firstly, there is a need to understand the direct role of the genes that have been identified within the context of MS, myelination, and central nervous system (CNS) function. Secondly, the findings of this study suggest that approximately 13% of the variance in MS severity could be attributed to low-frequency single nucleotide variation; however, this study did not have enough power to identify these variants. Dr Harroud suggests that increasing the sample size in future studies could help with this. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.